Tissue is the Issue When Performing a Biopsy for Potential Lung Cancer
July 15 2015 - 8:35AM
-Company Launches
GenCut(TM) Core Biopsy System for Minimally Invasive Use with the
superDimension(TM) Navigation System for Lung Tissue
Biopsies-
-Multiple Lung
Core Tissue Samples Now Possible with a Single Pass-
DUBLIN - July 15, 2015 -
Medtronic (NYSE:MDT) now offers the GenCut(TM) core biopsy system,
a unique lung tissue biopsy tool for use with the
superDimension(TM) navigation system. The superDimension(TM) system
enables a minimally invasive approach to accessing
difficult-to-reach areas of the lung, which can aid in the
diagnosis of lung cancer.
The GenCut core biopsy system is a unique tool
that allows pulmonologists and thoracic surgeons to collect
multiple core samples from lesions deep inside the lungs. With its
proprietary blade design, the GenCut core biopsy system can shear
and collect larger, more intact samples1, and allows
physicians to provide the pathology laboratory with tissue that
enables cytology, which is the microscopic appearance of cells,
histology and molecular profiling for personalized medicine. With
the ability to continuously sample, in one pass, physicians can
potentially decrease patients' biopsy procedure times.
"Lung cancer diagnostic clinicians consistently
state that tissue is the
issue. When performing a biopsy, they need enough tissue
for the pathologist to make a diagnosis and to ensure undamaged
tissue for genetic testing and molecular analysis. As lung cancer
drugs and therapies advance, the ability to provide earlier
diagnosis and earlier, personalized treatment can potentially save
lives," said Chuck Brynelsen, president, Early Technologies
business in Medtronic's Minimally Invasive Therapies
Group.
According to the American Lung Association, lung
cancer is the leading cause of cancer-related deaths in the United
States2. In its early
stages, lung cancer presents few, if any, symptoms. As a result,
the vast majority of lung cancer patients are diagnosed in the late
stages, when there is minimal chance for long-term survival.
Brynelsen concluded, "The continuum of care is the
healthcare journey a patient takes from diagnosis to recovery. Our
goal, across this continuum, is to diagnose earlier, intervene
earlier, treat better and help patients recover faster."
The GenCut core biopsy system received U.S. Food
and Drug Administration 510(k) clearance in April 2015.
Multimedia Release
A multimedia version of this release, with downloadable graphics
can be found at: http://bit.ly/1Hw8KFa
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is the global leader in medical technology - alleviating
pain, restoring health and extending life for millions of people
around the world.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 DVR00226
Study Report: A Chronic, GLP Study to Evaluate the Usability and
Safety of the Coring Tool in a Porcine Model, Sept 2014. Data on
file. Study not powered for significance.
2 American
Cancer Society: Cancer Facts & Figures 2014.
Contacts:
John Jordan
Public Relations
+1-508-452-4891
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#1928048
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024